Revasc
Withdrawn
This medicine's authorisation has been withdrawn
desirudin
Medicine
Human
Withdrawn
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
On 9 July 1997, the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Revasc, which had been approved for prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery. The marketing authorisation holder (MAH) responsible for Revasc was Canyon Pharmaceuticals Limited.
On 18 July 2014, the European Commission issued a decision to withdraw the marketing authorisation for Revasc, following its receipt of a letter dated 19 June 2014 notifying the Commission of the MAH’s decision to voluntarily withdraw the marketing authorisation for this product for commercial reason. Revasc was not marketed in any European country.
Pursuant to this decision, the European public assessment report for Revasc is updated to reflect that the marketing authorisation is no longer valid.
Product information
Latest procedure affecting product information:IAIN/0031/G
23/01/2012
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Revasc
- Active substance
- desirudin
- International non-proprietary name (INN) or common name
- desirudin
- Therapeutic area (MeSH)
- Venous Thrombosis
- Anatomical therapeutic chemical (ATC) code
- B01AE01
Pharmacotherapeutic group
Antithrombotic agentsTherapeutic indication
Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.
This page was last updated on